R&D Pipeline

Latest Competitive Analysis of Pfizer Drug Pipeline

19 October 2023
3 min read

In the wake of the receding tide of COVID-19 oral medication and vaccines, Pfizer seems to have returned to an awkward predicament where all potential growth points have fallen flat. 

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of Pfizer.

Palbociclib, Apixaban, Prevnar20 have all past their prime, and the only drug that shows a slight increase, Tafamidis, is merely a drop in the bucket. As a result, Pfizer’s market capitalization, which briefly reached over $300 billion in 2022, has recently returned to around $200 billion, causing Pfizer to drop to ninth place in the ranking of large pharmaceutical company market values.

图形用户界面, 应用程序

描述已自动生成

Pfizer is now looking to achieve growth through acquisitions, aiming to purchase $25 billion in revenue by 2030.

The most noteworthy recent R&D developments include the approval of the RSV vaccine and the CGRP migraine drug Zavegepant. Other noteworthy achievements include the approval of the BCMA×CD3 dual antibody Elranatamab, the approval of the JAK1 inhibitor Abrocitinib for adolescent Atopic Dermatitis indications, and the submission of applications for the S1PR modulator Etrasimod and the gene therapy SPK-9001. In addition, the Phase 3 clinical results for the Hemophilia drug TFPI monoclonal antibody Marstacimab have been released, and Pfizer decided between the two Oral GLP-1, abandoning Lotiglipron and pushing Danuglipron. While this long list may appear robust and impressive for a regular company, it seems somewhat insufficient for a top-tier pharmaceutical enterprise with a market capitalization in the hundreds of billions. It doesn't seem like there's anything that could form a strong pillar for rapid growth.

图形用户界面, 文本

描述已自动生成

Advances in Clinical Research on BRAF Inhibitor
Advances in Clinical Research on BRAF Inhibitor
19 October 2023
BRAF, a protein kinase, plays a crucial role in the human body by regulating cell growth and division.
Read →
KEYTRUDA® (pembrolizumab), a Merck product, met its main objective of disease-free survival (DFS) in specific patients with Muscle-Invasive Urothelial Carcinoma post-surgery
Latest Hotspot
3 min read
KEYTRUDA® (pembrolizumab), a Merck product, met its main objective of disease-free survival (DFS) in specific patients with Muscle-Invasive Urothelial Carcinoma post-surgery
19 October 2023
Merck recently proclaimed that the Phase 3 AMBASSADOR study assessing KEYTRUDA, an anti-PD-1 treatment developed by Merck.
Read →
Latest Competitive Analysis of Novartis Drug Pipeline
R&D Pipeline
3 min read
Latest Competitive Analysis of Novartis Drug Pipeline
19 October 2023
Despite Novartis being a consistent top contender in the pharmaceutical sector in terms of revenue, its growth and market value in recent years has been rather dismal.
Read →
Analysis on the Clinical Research Progress of Androgen Receptor Inhibitor
Analysis on the Clinical Research Progress of Androgen Receptor Inhibitor
19 October 2023
Androgen receptor (AR) is a type of nuclear receptor that is activated by binding of either of the androgenic hormones testosterone or dihydrotestosterone in the cytoplasm and then translocating into the nucleus.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.